Clinical trials: General Anesthetic
Anesthesia, General
Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)
The current trial was designed to demonstrate faster recovery from a neuromuscular blockade (NMB) induced by rocuronium after reversal at 1-2 Post Tetanic Count (PTC) by 4.0 mg.kg-1 sugammadex compared to 50 µg.kg-1 neostigmine…
- Trial name
- NCT00724932
- Testing
- Rocuronium, Sugammadex, Neostigmine
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Underdosing of Other General Anesthetics
Influence of Mild Hypothermia on Reversal of Rocuronium With Sugammadex
The primary efficacy endpoint is the time from the start of administration of sugammadex to recovery of the TOF ratio to 0.9 in deep neuromuscular block (1-2 twitches post-tetanic count) induced by rocuronium during mild…
- Trial name
- NCT01965067
- Testing
- sugammadex
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- MSD Korea Ltd.
Anesthesia Induced Hypothermia, Inadvertent Perioperative Hypothermia
Study to Evaluate Safety and Efficacy of Blanket Used to Prevent Anesthesia Induced Hypothermia
The investigation was designed as an Open-Label, Multicenter, Randomised, Controlled Investigation to Evaluate the Efficacy and Safety of the BARRIER® EasyWarm Active Self-Warming Blanket Used for Continuous Active Warming to…
- Trial name
- NCT01900067
- Testing
- BARRIER® EasyWarm Active Self-Warming Blanket
- Volunteers
- 271 people
- Sponsor
- Molnlycke Health Care AB
Anesthesia, General
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)
The objective of the trial was to establish the dose-response relation of sugammadex (Org 25969) given as a reversal agent of rocuronium or vecuronium at reappearance of T2 (the amplitude of the first response of second twitch to…
- Trial name
- NCT00552617
- Testing
- Sugammadex, Rocuronium, Vecuronium
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia
Efficacy and Safety of HSK3486 Compared to Propofol in Induction of General Anesthesia in Adults Having Elective Surgery
This is a multicenter, randomized, double-blinded, propofol-controlled, Phase 3 clinical study to evaluate the efficacy and safety of HSK3486 for induction of general anesthesia in adults undergoing elective surgery.
- Trial name
- NCT04711837
- Testing
- HSK3486, Propofol
- Where
- 13 sites in United States
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Haisco-USA Pharmaceuticals, Inc.
Neuromuscular Blockade
Incidence of Incomplete Postoperative Neuromuscular Recovery From Anesthesia (P07535)(Completed)
This is a multicenter, observational study in adult participants undergoing different types of elective surgical procedures requiring general anesthesia.
- Trial name
- INSPIRE (NCT01181349)
- Testing
- Neuromuscular Blocking Agent (NMBA)
- Volunteers
- 350 people
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia, General
Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)
The purpose of this study was to demonstrate in adult participants faster recovery from a neuromuscular block induced by either rocuronium or vecuronium after reversal at reappearance of T2 (the amplitude of the first response of…
- Trial name
- NCT00451217
- Testing
- Sugammadex, Neostigmine
- Volunteers
- 198 people
- Sponsor
- Merck Sharp & Dohme LLC
General Anesthesia
Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia
To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous [IV] slow injection over 30 [±5] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection…
- Trial name
- NCT05478174
- Testing
- HSK3486, Propofol
- Where
- 23 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Haisco-USA Pharmaceuticals, Inc.
Anesthesia, General
Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)
The purpose of the trial is to demonstrate a faster recovery from neuromuscular block induced by 1.2 mg/kg rocuronium after reversal at 3 minutes by 16.0 mg/kg of sugammadex compared with recovery after a neuromuscular block…
- Trial name
- NCT00474253
- Testing
- Sugammadex, Succinylcholine, Rocuronium
- Volunteers
- 115 people
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia, General
A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)
The objective of the trial was to establish the dose-response relation of sugammadex (Org 25969) given as a reversal agent of rocuronium or vecuronium at 1-2 PTC during sevoflurane anesthesia for Japanese participants.
- Trial name
- NCT00591786
- Testing
- Sugammadex
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia, General
Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)
The purpose of the study is to compare the effectiveness, safety and pharmacokinetics of sugammadex in participants 65 and over with participants under 65. There is no hypothesis defined for the study.
- Trial name
- NCT00474617
- Testing
- Sugammadex, Rocurium
- Volunteers
- 162 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Artery Disease, General Anesthetic Drug Allergy
Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery
Xenon is a gaseous anaesthetic agent registered in several European countries. It has been administered safely during cardiac surgery in pilot studies.
- Conditions
- Coronary Artery Disease, General Anesthetic Drug Allergy, Coronary Artery Bypass Graft Surgery
- Trial name
- NCT01294163
- Testing
- Xenon, Sevoflurane, Propofol
- Where
- 17 sites in France, Germany and 2 more
- Volunteers
- 509 people
- Sponsor
- Air Liquide Santé International
Anesthesia, General
Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane
This registry is primarily aiming to demonstrate the correlation between good practices of anesthesiologists and patient related outcomes including decreased overall anesthesia cost.
- Trial name
- NCT01199471
- Where
- 40 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Abbott
Anesthesia, General, Neuromuscular Blockade
Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)
The present trial was set up to evaluate the efficacy and safety of 2.0 mg.kg-1 sugammadex compared to neostigmine administered at reappearance of T2 in Chinese and Caucasian subjects for registration purposes in China.
- Trial name
- NCT00825812
- Testing
- Sugammadex, neostigmine
- Volunteers
- 308 people
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia, General, Neuromuscular Blockade
Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED)
The present trial is set up to evaluate the efficacy and safety of 4.0 mg.kg-1 sugammadex in Chinese and Caucasian subjects for registration purposes in China.
- Trial name
- NCT00826176
- Testing
- Sugammadex
- Volunteers
- 164 people
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia, General
Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)
The purpose of the trial is to research the safety and to show faster recovery after administration of 2.0 mg/kg or 4.0 mg/kg sugammadex (Org 25969, MK-8616) given as a reversal agent for 0.6 mg/kg (0.15 mg/kg maintenance dose)…
- Trial name
- NCT00475215
- Testing
- Sugammadex, Rocuronium
- Volunteers
- 86 people
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia, General
A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)
The objective of the trial was to establish the dose-response relation of sugammadex given as a reversal agent of rocuronium or vecuronium at 1-2 Post-Tetanic Count (PTC) during sevoflurane anesthesia for Caucasian participants
- Trial name
- NCT00552929
- Testing
- Sugammadex
- Volunteers
- 102 people
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia, General
Evaluation of Volatile Induction and Maintenance Anesthesia (VIMA) With Sevorane in Adult Patients Required General Anesthesia for Surgery in Terms of Quality of Anesthesia and Its Influence on Cardiovascular System in Common Clinical Practice
The main objective of this post-marketing observational study is to collect data from the use of general anesthesia in patients undergoing any surgery to create local recommendations.
- Trial name
- SEVOPROTECTION (NCT01282203)
- Where
- 12 sites in Kazakhstan
- Volunteers
- 1,122 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Anesthesia
Japan Phase 2/3 Clinical Study With BLM-240 (Desflurane)
The purposes of this study are to evaluate the efficacy and safety of desflurane (BLM-240) as an anesthetic agent and to demonstrate the non-inferiority of desflurane to sevoflurane in term of awakening/recovery from anesthesia.
- Trial name
- NCT00762372
- Testing
- desflurane, desflurane/nitrous oxide, sevoflurane/nitrous oxide
- Where
- 15 sites in Japan
- Volunteers
- 216 people
- Sponsor
- Baxter Healthcare Corporation
Anesthesia, General
Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)
The objective of this trial was to explore the dose-response relation of sugammadex (Org 25969; MK-8616) administered for the reversal of neuromuscular blockade (NMB) at 3 and 15 minutes following administration of 1.0 and 1.2…
- Trial name
- NCT00535743
- Testing
- Sugammadex, Esmeron®
- Volunteers
- 174 people
- Sponsor
- Merck Sharp & Dohme LLC